Skip to main content
. Author manuscript; available in PMC: 2008 Jul 2.
Published in final edited form as: Eur J Pharmacol. 2007 Mar 19;566(1-3):117–119. doi: 10.1016/j.ejphar.2007.03.007

Fig. 1.

Fig. 1

The PPAR-α receptor agonist GW7647 and the endocannabinoid anandamide synergistically inhibit pain behavior. A,B and D,E: Dose dependent inhibition of (A,D) phase I (0-15 min.) or (B,E) phase II (15-45 min) formalin-evoked pain behavior in Swiss mice by intraplantarly administered (A,D) anandamide (0.1-10 μg/paw), (B,E) GW7647 (0.1-10 μg/paw) or vehicle (V). C and F: Effects of anandamide (AEA, 0.1 μg/paw) alone or together with GW7647 (GW, 0.1μg/paw) in the presence or absence of SR141716A (SR1, 1 mg/kg, i.v.) on (C) phase I or (F) phase II formalin-evoked pain behavior in Swiss mice (n = 6-10) ** P < 0.01 vs. V.

HHS Vulnerability Disclosure